CTOs on the Move

Editas Medicine

www.editasmedicine.com

 
What if you could repair broken genes? That is the question we ask ourselves every day at Editas Medicine. We`re a leading genome editing company focused on translating the power and promise of our proprietary genome editing systems into medicines to help transform the lives of people with genetically-defined diseases. Our goal is to discover, develop, manufacture, and commercialize transformative medicines for a range of serious diseases, including eye diseases, blood diseases, and cancer. We are a vibrant company full of hope, possibilities, and a belief that, working together as One Editas, we can truly revolutionize the development of medicines. ...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Kevin Dushney
 Vice President of Technology Profile
Vic Myer
 Chief Technology Officer Profile

Funding

Editas Medicine raised $120M on 08/10/2015
Editas Medicine raised $215.6M on 06/23/2020
Editas Medicine raised $231M on 01/21/2021

Similar Companies

Affitech USA

Affitech USA is a Walnut Creek, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Medusa Medical Technologies Inc

Medusa Medical Technologies Inc is a Halifax, NS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Aimmune

Aimmune Therapeutics, Inc. is a biopharmaceutical company that aspires to become the global leader in developing curative therapies and solutions for patients with food allergies. With a mission to improve the lives of people with food allergies, Aimmune is developing and commercializing oral treatments for potentially life-threatening food allergies. The Company`s Characterized Oral Desensitization ImmunoTherapy (CODIT™) approach is intended to provide meaningful levels of protection against allergic reactions resulting from accidental exposure to food allergens by desensitizing patients with defined, precise amounts of key allergens. Aimmune has one FDA-approved medicine for peanut allergy and other investigational therapies in development to treat other food allergies. Aimmune is located in Brisbane, California - the heart of San Francisco`s biotechnology hub - with additional offices in the Kings Cross area of London and in Durham, North Carolina.

Galecto

Galecto is a clinical stage biotechnology company committed to the development of novel small molecule therapeutics directed at biological targets which are at the heart of fibrosis, inflammation, and cancer. Galecto was founded by leading fibrosis-focused scientists and biotech executives and is built on more than 10 years of research into galectin and fibrosis modulators. Our team has developed a deep understanding of the galectin family of proteins and the LOXL2 enzyme, and how both influence multiple biological pathways of these complex, often devastating, diseases. Galecto is funded by Novo Holdings, OrbiMed, Ysios, HBM Healthcare Investments, Sunstone Capital, M Ventures, Bristol-Myers Squibb, Maverick Ventures, Seventure and SEED Capital.

Bioscience

Bioscience, Inc. is a Bethlehem, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.